×

drug_alert95abacavir-hypersensitivity_respiratory_symptoms.pdf

Home / Discover /www.who.int/medicines/publications/drugalerts/

  Parent Folder


drug_alert95abacavir-hypersensitivity_respiratory_symptoms.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert96hypericum_perforatum-interactions_with_medicines.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert94levacetylmethadol_life_threatening_cardiac_rhythm_disorders.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert97pyrithione_zinc_spray_formulation_found_contain_corticosteroid.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert93unapproved_drugs_treatment_cancer.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert98_abacavir_hypersensitivity.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert92grepafloxacin_voluntarily_withdrawn.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert99etanercept-serious_haematological_reactions.pdf
PDF 4 years ago 96.04 kB
Copy Link   
drug_alert91leflunomide-pancytopenia_serious_skin_reactions.pdf
PDF 4 years ago Get Size
Copy Link   
ALERTE_OMSn1.2017_Vaccin_antimeningococcique_falsifieNiger.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert90quixil-reports_fatal_neurotoxic_reactions.pdf
PDF 4 years ago Get Size
Copy Link   
WHO_ALERTn1.2017_Falsified_meningitisVaccineNiger.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert89rotavirus_vaccine_withdrawn.pdf
PDF 4 years ago 167.47 kB
Copy Link   
WHO_ALERT_n2_2017french.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert88infusion_sets_stolen_before_being_sterilized.pdf
PDF 4 years ago Get Size
Copy Link   
WHO_ALERT_n2_2017english.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert87pramipexole-sudden_onset_sleep.pdf
PDF 4 years ago 103.86 kB
Copy Link   
WHO_ALERT_Avastin_and_SutentN3_2017ES.pdf
PDF 4 years ago Get Size
Copy Link   
drug_alert86trovafloxacin_alatrofloxacin-suspension_warnings.pdf
PDF 4 years ago 117.48 kB
Copy Link   
WHO_ALERT_Avastin_and_SutentN3_2017FR.pdf
PDF 4 years ago Get Size
Copy Link   

Join FilePursuit on FilePursuit Discord Server chat for discussions and more information.